一名65歲的陳太太為早期確診的乳癌患者，但去年發現腫瘤有復發轉移的情況，雖初期使用化學治療有效果，但維持不久又持續惡化，腫瘤不但變大又變多，並且副作用強烈，包含掉髮、噁心、嘔吐、體重直線下降等，更出現嚴重憂鬱狀況，生活品質非常不理想！
乳癌五年存活率達85% 晚期乳癌卻低於26%
根據SEER資料顯示，美國境內2017年新增乳癌266,120人，占全癌症的15%，五年存活率大約9成。台灣國健署最新資料顯示，民國104 年全癌症個案數為105,156 人，較103 年的103,147 人增加2,009人，其中乳癌發生率第一名，共12,360人，占全癌症發生人口12%，整體乳癌五年存活率達85%，但是晚期乳癌卻低於26%。
臺灣國健署公佈最新資料顯示，國人0 期乳癌5 年存活率約98%；Ⅰ期乳癌5 年存活率約96%；Ⅱ期乳癌5 年存活率約89%；至於III 期乳癌預後則不好，五年存活率約72%，而Ⅳ期5 年存活率低於26%。乳癌長年佔據女性癌症發生率之首，其中新診斷或復發的晚期乳癌因為通常無法手術切除，經常惡化速度較快，由此可見晚期乳癌治療的難處。
乳癌精準治療再增生力軍 CDK4/6抑制劑降低神經傷害
台北慈濟醫院癌症中心教研長暨台灣乳房醫學會理事長沈陳石銘教授表示，乳癌是台灣非常重要的公共衛生議題，診斷治療及預後追蹤需要更用心關注。沈陳石銘教授秉持著這樣的理念，鑽研於乳癌治療，積極與醫療研究團隊合作，期盼透過研究平台找到新的乳癌治療方向，期許即使乳癌復發轉移患者，在生命最後一段路，除了可以「活得有品質」，更希望患者感受到活下去的價值。
沈陳石銘教授表示，所幸近年來乳癌標靶治療的研究蓬勃發展，發現乳癌細胞生長週期蛋白依賴性激?4跟6（cyclin-dependent kinases，CDK4/6），而CDK4/6抑制劑可抑制癌細胞生長週期，使癌細胞無法生長，阻止癌細胞擴散。過去單獨使用抗荷爾蒙治療病患有2成的反應率，而依據國外研究顯示，有將近5成5患者對CDK4/6抑制劑治療反應有效；今年6月初，美國癌症醫學會年會(ASCO)中，更發表研究指出，CDK4/6抑制劑的作用，在停經前或停經後的女性都有相同的效果，相當令人振奮。
沈陳石銘教授進一步說明，台灣衛福部今年核准CDK4/6抑制劑可以搭配抗賀爾蒙藥物治療,使用於停經前或停經後,賀爾蒙接受體陽性, HER-2陰性之轉移性乳癌病患的初始治療，讓國內乳癌的精準治療再增生力軍。CDK4/6抑制劑不會造成神經性傷害，且還可降低患者疼痛，副作用大幅下降，可維持生活品質外，更能延長壽命、延後化療，除了讓患者增加與家人相處的時間，也不會因治療讓生活失去品質，讓患者活得更有價值。
laennec女性應定期乳房健檢 愈早發現治癒率高
沈陳石銘教授也呼籲，45歲至60歲的女性為乳癌的好發族群，但台灣年輕乳癌病患也逐年增加，雖然國健署僅補助特定年齡婦女乳癌篩檢，並不代表年輕女性就不需重視，建議千萬不要鐵齒，定期安排篩檢，愈早發現，治癒率相對也提高，目前乳癌第一期的五年存活率可達96%
A 65-year-old Mrs. Chen is an early-diagnosed breast cancer patient, but last year she found that the tumor had recurrence and metastasis. Although the initial use of chemotherapy was effective, it continued to deteriorate soon after the maintenance. The tumor not only became larger but also more, and the side effects were strong. , including hair loss, nausea, vomiting, weight loss, etc., more serious depression, quality of life is not ideal!
Breast cancer has a five-year survival rate of 85%. Late breast cancer is less than 26%.
According to SEER data, there are 266,120 new breast cancers in the United States in 2017, accounting for 15% of all cancers, and the five-year survival rate is about 90%. According to the latest information from the National Health Service of Taiwan, the total number of cancer cases in the Republic of China in the year of 105 was 105,156, an increase of 2,009 from 103,147 in 103 years. Among them, the incidence of breast cancer was the first, with a total of 12,360, accounting for 12% of the total cancer population. Breast cancer has a five-year survival rate of 85%, but advanced breast cancer is less than 26%.
According to the latest information released by the National Health Agency of Taiwan, the 5-year survival rate of stage 0 breast cancer is about 98%; the 5-year survival rate of stage I breast cancer is about 96%; the 5-year survival rate of stage II breast cancer is about 89%; the prognosis of stage III breast cancer is not Well, the five-year survival rate is about 72%, while the 4-year 5-year survival rate is less than 26%. Breast cancer accounts for the highest incidence of cancer in women for a long time. Among them, newly diagnosed or relapsed advanced breast cancer often fails to be surgically removed, and often deteriorates rapidly. This shows the difficulty in the treatment of advanced breast cancer.
Breast cancer precision treatment and proliferative force CDK4/6 inhibitor reduces nerve damage
Professor Chen Chenming, the director of the Cancer Research Center of the Tzu Chi Hospital in Taipei and the director of the Taiwan Breast Medicine Association, said that breast cancer is a very important public health issue in Taiwan. Diagnostic treatment and prognosis tracking need to be more concerned. Professor Shen Chen Shiming adheres to this philosophy and is studying breast cancer treatment. He actively cooperates with the medical research team and hopes to find a new direction of breast cancer treatment through the research platform. It is hoped that even if the breast cancer recurrence and metastasis patients, in the last part of life, in addition to being able to live Have quality, and hope that patients will feel the value of living.
Professor Shen Chenming said that fortunately, research on breast cancer target treatment has flourished in recent years, and found that breast cancer cells grow cycle-dependent kinases 4 and 6 (cyclin-dependent kinases, CDK4/6), while CDK4/6 inhibitors can inhibit cancer. The cell growth cycle prevents cancer cells from growing and prevents cancer cells from spreading. In the past, anti-hormone treatment alone used 20% of the response rate, and according to foreign studies, nearly 55% of patients were effective in responding to CDK4/6 inhibitor therapy; in early June this year, the American Association of Cancer Medicine Annual Meeting (ASCO) In addition, studies have indicated that the effects of CDK4/6 inhibitors have the same effect on women before or after menopause, which is quite exciting.
Professor Shen Chen Shiming further explained that Taiwan’s Weifu Department approved this year that CDK4/6 inhibitors can be combined with anti-hormone drugs for use in pre-menopausal or postmenopausal, hormone-positive, HER-2-negative metastatic breast cancer patients. The initial treatment allows the precision treatment of domestic breast cancer to proliferate. CDK4/6 inhibitors do not cause neurological damage, and can also reduce pain, reduce side effects, maintain quality of life, and prolong life and delay chemotherapy, in addition to increasing the time for patients to get along with their families. It will make life lose quality due to treatment, and make patients live more valuable.
Women should have regular breast health checks. The sooner they are found, the higher the cure rate.
Professor Shen Chenming also called on women aged 45 to 60 to be a good group of breast cancer, but young breast cancer patients in Taiwan have also increased year by year. Although the National Health Service only subsidizes breast cancer screening for women of certain ages, it does not mean that young women do not. Need to pay attention to, it is recommended not to iron teeth, regularly arrange screening, the sooner found, the cure rate is also relatively improved, the current five-year survival rate of breast cancer can reach 96%
Laennec is the ethical drug manufactured with JBP’s unique technologies.
Laennec is the ethical drug manufactured with JBP’s unique technologies for effective extraction of variety of growth factors, cytokines, and other physiologically active substances from the human placenta. For instance, HGF (hepatocyte growth factor) promotes the proliferation of hepatic parenchymal cells for recovery of a damaged liver. Our product safety is ensured by the most rigid safety measures among existing scientific standards.
留言列表
